Recently, local pharmaceutical companies have successively reviewed a number of large varieties of drugs

In recent years, with the accelerated promotion of innovation in the domestic pharmaceutical industry, a large number of new drugs have begun to emerge in the industry one after another
.
It is understood that a number of large varieties of drugs have been approved in succession in recent days
.
2 billion injections, reviewed by the top pharmaceutical companies in Shandong A few days ago, the website of the State Food and Drug Administration showed that Shandong Qidu Pharmaceutical/Shandong Yumankun Bio was approved for production of piracetam injections reported as imitations of Class 3 and regarded as the same Overrated
.
The data show that piracetam is a cyclic derivative of γ-aminobutyric acid, which is a drug for improving brain metabolism and has the effect of resisting brain function damage caused by physical, chemical and other factors
.
At present, the main dosage forms of piracetam that have been marketed in China include injections, tablets, granules, etc.
, of which injections are the main form
.
Data shows that in 2020, the market size of the terminal piracetam injection in China's public medical institutions is close to 2 billion yuan, a year-on-year increase of 37.
33%
.
In addition to Shandong Qidu Pharmaceutical/Shandong Yumankun Bio, there are 3 pharmaceutical companies that submitted piracetam injection marketing applications under the new registration classification
.
Among them, 2 pharmaceutical companies have submitted supplementary applications for the consistency evaluation of the product, which are under review and approval
.
On April 15, Sialon Pharmaceuticals announced that the company’s wholly-owned subsidiary Hunan Sialon Pharmaceuticals’ Tigecycline for Injection and Thymosarcine for Injection have passed the same approval.
Sexual evaluation
.
Tigecycline, a glycylcycline anti-infective drug, is clinically used for complex intra-abdominal infections, complex skin and skin and soft tissue infections, and community-acquired bacterial pneumonia caused by sensitive strains of specific bacteria
.
Thymosin for injection is a polypeptide immunomodulator, which is used for the treatment of chronic viral infection, adjuvant therapy of tumors and immunodeficiency patients, and as a vaccine enhancer; it is also widely used in various diseases such as hepatitis B, hepatitis C, cancer, and immune deficiency.
application value
.
It is a category B catalogue of national medical insurance
.
The data shows that the sales volume of these two injections in China's public medical institutions will exceed 1 billion yuan in 2020.

.
Among them, the terminal sales of tigecycline for injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in 2020 will be close to 2.
5 billion yuan, a year-on-year increase of 6.
42% in the first half of 2021
.
In 2020, the sales of thymosin for injection in the hospital will be nearly 1.
5 billion yuan
.
Two blockbuster generic drugs of Yangzijiang Pharmaceutical were approved for listing on the same day On April 15, NMPA released a new batch of drug approval documents, of which two generic drugs of Yangzijiang Pharmaceutical were approved for listing, namely Olmesartan Medoxomil and Shugeng Sodium Glucose Injection
.
Among them, Shugeng Sodium Glucose Injection was previously exclusively produced and sold by the original researcher Merck & Co.
, and Yangzijiang Pharmaceutical was approved as the first imitation in China
.
It is understood that sugammadex sodium injection is the world's first specific and binding amino steroid muscle relaxant antagonist
.
The drug was originally developed by Merck and was launched in Europe in July 2008 under the trade name Bridion
.
According to Merck's annual report, revenue in 2021 will reach US$1.
532 billion (about 9.
76 billion yuan, calculated at the exchange rate on April 15), an increase of 27%
.
In China, in 2020, the in-hospital sales of Shugeng Sodium Glucose has also exceeded 100 million.
In the first three quarters of 2021, it has achieved sales of more than 200 million, a year-on-year increase of 167%.
The market has grown strongly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.